Global CAR T-Cell Therapy Market Report and Forecast 2024-2032

Global CAR T-Cell Therapy Market Outlook

The global CAR T-cell therapy market size was valued at USD 2.5 billion in 2023, driven by the rising prevalence of cancer across the globe. The market is expected to grow at a CAGR of 15.2% during the forecast period of 2024-2032, with the values likely to rise from USD 2.9 billion in 2024 to USD 9.0 billion by 2032.

Global CAR T-Cell Therapy Market Overview

Chimeric antigen receptor (CAR) T-cell therapy is a method of modifying the immune cells, also known as T-cells to fight and destroy cancerous cells in the body. The market demand is majorly driven by growing incidence of cancer. CAR T-cell therapy has also garnered substantial excitement amongst researchers owing to ability to eradicate advanced leukaemia and lymphomas. The market is further propelled by rising investments on CAR T-cell related research and development and subsequent growth in number of FDA approvals for new therapies.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Incidence of Cancer Cases

In 2023, cancer is expected to affect approximately 2 million people in the United States. Non-Hodgkin Lymphoma and Leukaemia are one of the top 12 cancers expected to affect around 80,550 and 59,610 patients respectively. Out of the two, leukaemia is anticipated to cause 23,710 deaths while Non-Hodgkin Lymphoma may lead to 20,180 deaths. Hence, the CAR T-cell therapy market demand is projected to surge in upcoming years, as researchers aim at maximising its application to offer improved patient solutions.

Rising Collaborations Between Key Players

In December 2023, AbelZeta and AstraZeneca entered a partnership to develop the autologous, armoured GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, C-CAR031, designed to treat hepatocellular carcinoma (HCC). C-CAR031 leverages AstraZeneca’s growth factor-beta receptor II (TGFβRII) dominant negative armouring discovery platform along with AbelZeta’s cell therapies. The project pipeline also constitutes tumour-infiltrating lymphocyte therapies. Together, the companies envision at bringing effective and innovative therapeutic alternatives for patients. This also demonstrates the current trend of increasing collaborations which is expected to aid CAR T-cell therapy market growth in upcoming years.

In November 2023, Kite and Arcellx , announced the expansion of their existing partnership, which constituted the development and commercialisation of CART-ddBCMA for relapsed or refractory multiple myeloma. As per the renewal of their agreement, the collaboration will now include lymphomas as well. The candidate is currently under phase 2 clinical development and been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the FDA as well.

Growth in Research Activities to Boost the CAR T-cell Therapy Market Size

With rising technical advancements and deeper understanding of genetics, there has been significant development in CAR-T cell therapies trials. In August 2023, Cellectis provided an update on their ongoing three clinical trials and their evaluation. UCART123, an allogenic CAR-T therapy which targets CD123, occurring in patients with relapsed acute myeloid leukaemia (AML), demonstrated improved anti-tumour activity by sustained lymphodepletion and higher UCART123 cell expansion.

Technical Advancements Fuel a Surge in Approvals

In December 2023, the FDA approved Kite’s Yescarta ® (axicabtagene ciloleucel) CAR T-cell therapy label update. It is the first and only treatment to showcase overall improved survival data for patients with refractory large B-cell lymphoma. The approval is based on the results from ZUMA-7 study which indicated a 27.4% reduction in the death risk when compared to second of care.

In November 2023, Immix Biopharma, Inc. IMMX also revealed that they had received the FDA approval for their new investigational drug which helps the application of NEXICART-2 (NCT06097832) on clinical studies for treatment of relapsed AL amyloidosis. The growth in approvals by the regulatory authorities display a significant CAR T-cell therapy market trend which is projected to help in the market growth in upcoming years.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global CAR T-Cell Therapy Market Segmentation

Market Breakup by Drug Type

• Axicabtagene Ciloleucel

• Tisagenlecleucel

• Brexucabtagene Autoleucel

• Lisocabtagene Maraleuce

• Idecabtagene Vicleucel

• Ciltacabtegene Autoleucel

• Others

Market Breakup by Antigen

• CD19

• BCMA

• HER2

• GD2

• CD22

• CD30

• CD33

• HER1

• CLDN18

Market Breakup by Application

• Acute Lymphocytic Leukemia

• Chronic Lymphocytic Leukemia

• Diffuse Large B-Cell Lymphoma (DLBCL)

• Follicular Lymphoma

• Mantle Cell Lymphoma

• Multiple Myeloma

• Glioblastoma

• Sarcoma

• Neuroblastoma

• Acute Myeloid Leukemia

• Breast Cancer

• Pancreatic Cancer

• Hepatocellular Carcinoma

• Colorectal Cancer

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global CAR T-Cell Therapy Market Regional Analysis

The United States is expected to lead the CAR T-cell therapy market share in the forecast period. This can be attributed to an increased emphasis on providing customised patient care solutions. The rising prevalence of cancer along with existence of key healthcare companies plays a pivotal role in the market growth. The surge in research and development activities is a major element as well.

In the forecast period, Asia Pacific is expected to witness a significant surge in the market value, with countries like India, China and Japan being a centre of attraction. India is expected to grow owing to increasing healthcare infrastructure development and rise in the foreign investments. In October 2023, Immunoadoptive Cell Therapy (ImmunoACT), an IIT Bombay incubated company received the Central Drugs Standard Control Organisation’s (CDSO) marketing authorisation for the first humanised CD19-targeted CAR T-cell therapy product in India. This showcases that the market is expected to emerge significantly in the upcoming years.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global CAR T-Cell Therapy Market: Competitor Landscape

In July 2023, Pfizer invested USD 25 million equity investment in Caribou Biosciences to develop and extensive allogeneic CAR-T cell therapy for multiple myeloma. The United States based biotech company will invest the money into CB-011, its allogeneic CAR-T cell therapy, which is being studied in a phase 1 clinical trial in patients. It targets the B-cell maturation antigen and is intended to remove the B2M protein and insert a B2M-HLA-E fusion protein to inhibit immune-mediated rejection.

In December 2023, FUJIFILM also announced their USD 200 million investment in cell therapies. This investment is intended to strengthen the company’s manufacturing capacity to support iPSC-derived cell therapies, as well as chimeric antigen receptor (CAR), T-cell receptor (TCR), cytoxic T lymphocyte (CTL), natural killer (NK) and tissue-derived therapies. The rising investments and portfolio expansions demonstrate a generic market trend wherein several companies are stepping in to solidify their presence in the market.

The key features of the CAR T-cell therapy market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Autolus Therapeutics

• CARsgen Therapeutics Co.Ltd.

• Juno Therapeutics, Inc.

• Sorrento Therapeutics, Inc.

• Bluebird bio, Inc.

• CELGENE CORPORATION

• Eureka Therapeutics Inc.

• Avacta Life Sciences Ltd.

• Calyxt Inc.

• Celyad Oncology SA

• Fortress Biotech, Inc

• IMMUNE THERAPEUTICS, INC

• Alaunos Therapeutics, Inc.

• Novartis AG

• Gilead Sciences, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

CAR T-Cell Therapy Market Report Snapshots

CAR T-Cell Therapy Market Size

CAR T-Cell Therapy Market Analysis

CAR T-Cell Therapy Companies